BACKGROUND: We sought to ascertain the immune effector function of pembrolizumab within the glioblastoma (GBM) microenvironment during the therapeutic window. METHODS: In an open-label, single-center, single-arm phase II "window-of-opportunity" trial in 15 patients with recurrent (operable) GBM receiving up to 2 pembrolizumab doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities occurred, immune responses were evaluated within the tumor. RESULTS: No treatment-related deaths occurred. Overall median follow-up time was 50 months. Of 14 patients monitored, 10 had progressive disease, 3 had a partial response, and 1 had stable disease. Median progression-free survival (PFS) was 4.5 months (95% CI: 2.27, 6.83), and the 6-month PFS rate was 40%. Median overall survival (OS) was 20 months, with an estimated 1-year OS rate of 63%. GBM patients' recurrent tumors contained few T cells that demonstrated a paucity of immune activation markers, but the tumor microenvironment was markedly enriched for CD68+ macrophages. CONCLUSIONS: Immune analyses indicated that pembrolizumab anti-programmed cell death 1 (PD-1) monotherapy alone can't induce effector immunologic response in most GBM patients, probably owing to a scarcity of T cells within the tumor microenvironment and a CD68+ macrophage preponderance.
BACKGROUND: We sought to ascertain the immune effector function of pembrolizumab within the glioblastoma (GBM) microenvironment during the therapeutic window. METHODS: In an open-label, single-center, single-arm phase II "window-of-opportunity" trial in 15 patients with recurrent (operable) GBM receiving up to 2 pembrolizumab doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities occurred, immune responses were evaluated within the tumor. RESULTS: No treatment-related deaths occurred. Overall median follow-up time was 50 months. Of 14 patients monitored, 10 had progressive disease, 3 had a partial response, and 1 had stable disease. Median progression-free survival (PFS) was 4.5 months (95% CI: 2.27, 6.83), and the 6-month PFS rate was 40%. Median overall survival (OS) was 20 months, with an estimated 1-year OS rate of 63%. GBMpatients' recurrent tumors contained few T cells that demonstrated a paucity of immune activation markers, but the tumor microenvironment was markedly enriched for CD68+ macrophages. CONCLUSIONS: Immune analyses indicated that pembrolizumab anti-programmed cell death 1 (PD-1) monotherapy alone can't induce effector immunologic response in most GBMpatients, probably owing to a scarcity of T cells within the tumor microenvironment and a CD68+ macrophage preponderance.
Authors: Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim Journal: Clin Cancer Res Date: 2016-06-29 Impact factor: 12.531
Authors: Jun Wei; Edjah K Nduom; Ling-Yuan Kong; Yuuri Hashimoto; Shuo Xu; Konrad Gabrusiewicz; Xiaoyang Ling; Neal Huang; Wei Qiao; Shouhao Zhou; Cristina Ivan; Greg N Fuller; Mark R Gilbert; Willem Overwijk; George A Calin; Amy B Heimberger Journal: Neuro Oncol Date: 2015-12-11 Impact factor: 12.300
Authors: Sarah T Garber; Yuuri Hashimoto; Shiao-Pei Weathers; Joanne Xiu; Zoran Gatalica; Roel G W Verhaak; Shouhao Zhou; Gregory N Fuller; Mustafa Khasraw; John de Groot; Sandeep K Reddy; David Spetzler; Amy B Heimberger Journal: Neuro Oncol Date: 2016-07-01 Impact factor: 12.300
Authors: Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon Journal: Lancet Oncol Date: 2015-11 Impact factor: 41.316
Authors: Nicholas Butowski; Howard Colman; John F De Groot; Antonio M Omuro; Lakshmi Nayak; Patrick Y Wen; Timothy F Cloughesy; Adhirai Marimuthu; Sam Haidar; Arie Perry; Jason Huse; Joanna Phillips; Brian L West; Keith B Nolop; Henry H Hsu; Keith L Ligon; Annette M Molinaro; Michael Prados Journal: Neuro Oncol Date: 2015-10-08 Impact factor: 12.300
Authors: Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce Journal: Nat Med Date: 2013-09-22 Impact factor: 53.440
Authors: Tiffany R Hodges; Martina Ott; Joanne Xiu; Zoran Gatalica; Jeff Swensen; Shouhao Zhou; Jason T Huse; John de Groot; Shulin Li; Willem W Overwijk; David Spetzler; Amy B Heimberger Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300
Authors: Mira A Patel; Jennifer E Kim; Debebe Theodros; Ada Tam; Esteban Velarde; Christina M Kochel; Brian Francica; Thomas R Nirschl; Ali Ghasemzadeh; Dimitrios Mathios; Sarah Harris-Bookman; Christopher C Jackson; Christina Jackson; Xiaobu Ye; Phuoc T Tran; Betty Tyler; Vladimir Coric; Mark Selby; Henry Brem; Charles G Drake; Drew M Pardoll; Michael Lim Journal: J Immunother Cancer Date: 2016-05-17 Impact factor: 13.751
Authors: Pakawat Chongsathidkiet; Christina Jackson; Shohei Koyama; Franziska Loebel; Xiuyu Cui; S Harrison Farber; Karolina Woroniecka; Aladine A Elsamadicy; Cosette A Dechant; Hanna R Kemeny; Luis Sanchez-Perez; Tooba A Cheema; Nicholas C Souders; James E Herndon; Jean-Valery Coumans; Jeffrey I Everitt; Brian V Nahed; John H Sampson; Michael D Gunn; Robert L Martuza; Glenn Dranoff; William T Curry; Peter E Fecci Journal: Nat Med Date: 2018-08-13 Impact factor: 53.440
Authors: Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger Journal: Clin Cancer Res Date: 2020-06-18 Impact factor: 12.531
Authors: Jun Wei; Peiwen Chen; Pravesh Gupta; Martina Ott; Daniel Zamler; Cynthia Kassab; Krishna P Bhat; Michael A Curran; John F de Groot; Amy B Heimberger Journal: Neuro Oncol Date: 2020-02-20 Impact factor: 12.300
Authors: Visish M Srinivasan; Chibawanye Ene; Brittany Parker Kerrigan; Frederick F Lang Journal: Neurosurg Clin N Am Date: 2020-11-05 Impact factor: 2.509
Authors: Pavlina Chuntova; Frances Chow; Payal B Watchmaker; Mildred Galvez; Amy B Heimberger; Evan W Newell; Aaron Diaz; Ronald A DePinho; Ming O Li; E John Wherry; Duane Mitchell; Masaki Terabe; Derek A Wainwright; Jay A Berzofsky; Christel Herold-Mende; James R Heath; Michael Lim; Kim A Margolin; E Antonio Chiocca; Noriyuki Kasahara; Benjamin M Ellingson; Christine E Brown; Yvonne Chen; Peter E Fecci; David A Reardon; Gavin P Dunn; Linda M Liau; Joseph F Costello; Wolfgang Wick; Timothy Cloughesy; William C Timmer; Patrick Y Wen; Robert M Prins; Michael Platten; Hideho Okada Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300